Oncimmune Stock Price, News & Analysis (LON:ONC)

GBX 90
0.00 (0.00 %)
(As of 09/23/2019 04:53 AM ET)
Today's Range
Now: GBX 90
50-Day Range
MA: GBX 92.73
52-Week Range
Now: GBX 90
Volume17,133 shs
Average Volume33,554 shs
Market Capitalization£56.93 million
P/E RatioN/A
Dividend YieldN/A
Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma (HCC) in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.

Industry, Sector and Symbol

Industry Diagnostics & Research



Sales & Book Value

Annual Sales£284,000.00
Cash FlowGBX 14.70 per share
Book ValueGBX 15.90 per share



Market Cap£56.93 million
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Oncimmune (LON:ONC) Frequently Asked Questions

What is Oncimmune's stock symbol?

Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."

How were Oncimmune's earnings last quarter?

Oncimmune Holdings PLC (LON:ONC) released its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) earnings per share (EPS) for the quarter. The firm earned $0.08 million during the quarter. View Oncimmune's Earnings History.

When is Oncimmune's next earnings date?

Oncimmune is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Oncimmune.

Has Oncimmune been receiving favorable news coverage?

News headlines about ONC stock have been trending somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncimmune earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Oncimmune.

Who are some of Oncimmune's key competitors?

Who are Oncimmune's key executives?

Oncimmune's management team includes the folowing people:
  • Dr. Adam Mark Hill Ph.D., CEO & Director (Age 39)
  • Mr. Andrew Millet BA, FCA, MBA, Exec. (Age 52)
  • Mr. Matthew Hall, Group Chief Financial Officer
  • Dr. Laura J. Peek, Principal Scientist & Assistant Lab Director
  • Mr. Andrew Stewart, Gen. Counsel & Company Sec.

How do I buy shares of Oncimmune?

Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Oncimmune's stock price today?

One share of ONC stock can currently be purchased for approximately GBX 90.

How big of a company is Oncimmune?

Oncimmune has a market capitalization of £56.93 million and generates £284,000.00 in revenue each year. Oncimmune employs 52 workers across the globe.View Additional Information About Oncimmune.

What is Oncimmune's official website?

The official website for Oncimmune is http://oncimmune.com/.

How can I contact Oncimmune?

Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.

MarketBeat Community Rating for Oncimmune (LON ONC)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about Oncimmune and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel